5-251425-C-T
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PP3_Moderate
The NM_004168.4(SDHA):c.1751C>T(p.Ala584Val) variant causes a missense change. The variant allele was found at a frequency of 0.0000973 in 1,613,836 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. A584A) has been classified as Benign.
Frequency
Consequence
NM_004168.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SDHA | NM_004168.4 | c.1751C>T | p.Ala584Val | missense_variant | Exon 13 of 15 | ENST00000264932.11 | NP_004159.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SDHA | ENST00000264932.11 | c.1751C>T | p.Ala584Val | missense_variant | Exon 13 of 15 | 1 | NM_004168.4 | ENSP00000264932.6 | ||
ENSG00000286001 | ENST00000651543.1 | n.*484C>T | non_coding_transcript_exon_variant | Exon 12 of 24 | ENSP00000499215.1 | |||||
ENSG00000286001 | ENST00000651543.1 | n.*484C>T | 3_prime_UTR_variant | Exon 12 of 24 | ENSP00000499215.1 |
Frequencies
GnomAD3 genomes AF: 0.0000854 AC: 13AN: 152184Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000916 AC: 23AN: 251008Hom.: 0 AF XY: 0.0000884 AC XY: 12AN XY: 135698
GnomAD4 exome AF: 0.0000985 AC: 144AN: 1461652Hom.: 0 Cov.: 32 AF XY: 0.0000894 AC XY: 65AN XY: 727136
GnomAD4 genome AF: 0.0000854 AC: 13AN: 152184Hom.: 0 Cov.: 32 AF XY: 0.0000673 AC XY: 5AN XY: 74344
ClinVar
Submissions by phenotype
not provided Pathogenic:1
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; While this variant is considered pathogenic for autosomal recessive Complex II deficiency, its association with autosomal dominant Hereditary Paraganglioma/Pheochromocytoma syndrome is unclear; Observed in a patient with paraganglioma; this patient also had a variant in the SDHB gene with loss of SDHB expression in the tumor (PMID: 35546442); This variant is associated with the following publications: (PMID: 30680959, 28546994, 35546442) -
not specified Uncertain:1
Variant summary: SDHA c.1751C>T (p.Ala584Val) results in a non-conservative amino acid change located in the C-terminal domain (IPR015939) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. Additionally, several computational tools predict a significant impact on normal splicing: Three predict the variant creates a 5' donor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 9.2e-05 in 251008 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.1751C>T has been reported in the literature in at least one individual affected with paraganglioma (e.g., Ding_2022), however, the variant was found to co-occur with another pathogenic variant (SDHB c.3G>A, p.M1I), providing supporting evidence for a benign role. This report therefore does not provide unequivocal conclusions about association of the variant with SDHA-related disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication was ascertained in the context of this evaluation (PMID: 35546442). ClinVar contains an entry for this variant (Variation ID: 239657). Based on the evidence outlined above, the variant was classified as uncertain significance. -
Paragangliomas 5;C5700310:Mitochondrial complex II deficiency, nuclear type 1 Uncertain:1
This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 584 of the SDHA protein (p.Ala584Val). RNA analysis indicates that this missense change induces altered splicing and likely results in the loss of 15 amino acid residue(s), but is expected to preserve the integrity of the reading-frame. This variant is present in population databases (rs201068049, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with SDHA-related conditions. ClinVar contains an entry for this variant (Variation ID: 239657). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt SDHA protein function with a negative predictive value of 95%. Studies have shown that this missense change results in the activation of a cryptic splice site in exon 13 (internal data). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Dilated cardiomyopathy 1GG Uncertain:1
- -
Hereditary cancer-predisposing syndrome Uncertain:1
The c.1751C>T variant (also known as p.A584V), located in coding exon 13 of the SDHA gene, results from a C to T substitution at nucleotide position 1751. The alanine at codon 584 is replaced by valine, an amino acid with similar properties. This nucleotide position is well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will result in the creation or strengthening of a novel splice donor site. RNA studies have demonstrated that this alteration results in an incomplete splice defect; the clinical impact of this abnormal splicing is unknown at this time (Ambry internal data). In addition, this variant has been detected in multiple heterozygous and homozygous individuals with no reported features of SDHA-associated disease (Ambry internal data). Since supporting evidence is conflicting at this time, the clinical significance of this alteration remains unclear. -
SDHA-related disorder Uncertain:1
The SDHA c.1751C>T variant is predicted to result in the amino acid substitution p.Ala584Val. This variant is predicted to activate a cryptic splice donor site in exon 13 based on available splicing prediction programs (SpliceAI, Jaganathan et al. 2019. PubMed ID: 30661751), however mRNA studies have not been reported in the literature. To our knowledge, this variant has not been reported in individuals with SDHA-associated disorders in the literature. An alternate substitution of this amino acid (p.Ala584Thr) has been reported with uncertain significance in a cohort of individuals with breast cancer (McDonald et al. 2022. PubMed ID: 36315513). This variant is reported in 0.021% of alleles in individuals of European (Non-Finnish) descent in gnomAD, and has conflicting interpretations of pathogenicity in ClinVar ranging from uncertain to likely pathogenic (http://www.ncbi.nlm.nih.gov/clinvar/variation/239657). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at